LP
CBIO

LMR Partners’s Crescent Biopharma CBIO Stock Holding History

LMR Partners’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-141
Closed -$3.97K – 1415
2024
Q2 		$3.97K Hold
141
– – ﹤0.01% 1048
2024
Q1 		$42.3K Buy
+141
New +$42.1K ﹤0.01% 995
2021
Q3 		– Sell
-229
Closed -$53K – 1075
2021
Q2 		$53K Buy
+229
New +$58.3K ﹤0.01% 983
2021
Q1 		– Sell
-105
Closed -$40K – 1003
2020
Q4 		$40K Sell
105
-45
-30% -$15.8K ﹤0.01% 468
2020
Q3 		$46K Hold
150
– – ﹤0.01% 392
2020
Q2 		$57K Buy
+150
New +$42.5K ﹤0.01% 526
2014
Q3 		– Sell
-197
Closed -$166K – 390
2014
Q2 		$166K Buy
+197
New +$196K 0.01% 415

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return